Mineralys Therapeutics Inc
MLYS13.625USD
-0.040-0.29%
交易中 （美東）報價延遲15分鐘
883.94M總市值
虧損本益比TTM
關於 Mineralys Therapeutics Inc 公司
Mineralys Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發針對高血壓、慢性腎病 (CKD) 和其他由醛固酮異常升高引起的疾病的藥物。該公司的候選產品 lorundrostat 是一種專有的口服高選擇性醛固酮合酶抑制劑 (ASI)，該公司最初正在開發用於治療不受控制的高血壓 (uHTN) 患者。Lorundrostat 旨在通過抑制負責產生激素的酶 CYP11B2 來降低醛固酮水平。該公司完成了 Target-HTN 試驗，這是一項針對 lorundrostat 治療 uHTN 的 II 期概念驗證試驗。除了高血壓之外，該公司還打算開發用於治療慢性腎病 (CKD) 的 lorundrostat。
公司簡介
公司代碼MLYS
公司名稱Mineralys Therapeutics Inc
上市日期Feb 10, 2023
CEOMr. Jon Congleton
員工數量51
證券類型Ordinary Share
年結日Feb 10
公司地址150 N. Radnor Chester Road
城市RADNOR
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編19087
電話18883786240
網址https://mineralystx.com/
公司代碼MLYS
上市日期Feb 10, 2023
CEOMr. Jon Congleton
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月19日 週六
更新時間: 7月19日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
持股股東
持股股東
佔比
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
股東類型
持股股東
佔比
Investment Advisor
38.81%
Hedge Fund
23.09%
Venture Capital
22.96%
Investment Advisor/Hedge Fund
16.44%
Individual Investor
1.40%
Research Firm
1.10%
Pension Fund
0.67%
Private Equity
0.61%
Bank and Trust
0.09%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
285
69.20M
106.19%
+10.20M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
2023Q1
99
41.30M
101.10%
+30.53M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Catalys Pacific, LLC
8.64M
13.26%
--
--
Mar 31, 2025
RA Capital Management, LP
6.15M
9.43%
+1.30M
+26.72%
Mar 31, 2025
Samsara BioCapital, LLC
5.67M
8.71%
+600.00K
+11.82%
Mar 31, 2025
SR One Capital Management, LP
3.13M
4.8%
+1.11M
+55.09%
Mar 31, 2025
TCG Crossover Management, LLC
2.47M
3.79%
--
--
Mar 31, 2025
Integral Health Asset Management, LLC
2.30M
3.53%
+1.43M
+162.86%
Mar 31, 2025
HBM Partners AG
2.25M
3.45%
--
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.20M
3.38%
+266.41K
+13.75%
Mar 31, 2025
Caligan Partners, LP
2.15M
3.3%
+1.14M
+112.60%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.82%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.12%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.06%
iShares Russell 2000 Growth ETF
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
ProShares UltraPro Russell2000
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.82%
SPDR S&P Biotech ETF
佔比0.2%
iShares Micro-Cap ETF
佔比0.12%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.11%
ProShares Ultra Nasdaq Biotechnology
佔比0.1%
Invesco Nasdaq Biotechnology ETF
佔比0.1%
iShares Biotechnology ETF
佔比0.06%
iShares Russell 2000 Growth ETF
佔比0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0.03%
ProShares UltraPro Russell2000
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
